| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 21287.
aAuthor for correspondence.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Methods: We screened for potential tumor biomarkers in 169 serum samples, including samples from a cancer group of 103 breast cancer patients at different clinical stages [stage 0 (n = 4), stage I (n = 38), stage II (n = 37), and stage III (n = 24)], from a control group of 41 healthy women, and from 25 patients with benign breast diseases. Diluted serum samples were applied to immobilized metal affinity capture Ciphergen ProteinChip® Arrays previously activated with Ni2+. Proteins bound to the chelated metal were analyzed on a ProteinChip Reader Model PBS II. Complex protein profiles of different diagnostic groups were compared and analyzed using the ProPeak software package.
Results: A panel of three biomarkers was selected based on their collective contribution to the optimal separation between stage 0–I breast cancer patients and noncancer controls. The same separation was observed using independent test data from stage II–III breast cancer patients. Bootstrap cross-validation demonstrated that a sensitivity of 93% for all cancer patients and a specificity of 91% for all controls were achieved by a composite index derived by multivariate logistic regression using the three selected biomarkers.
Conclusions: Proteomics approaches such as SELDI mass spectrometry, in conjunction with bioinformatics tools, could greatly facilitate the discovery of new and better biomarkers. The high sensitivity and specificity achieved by the combined use of the selected biomarkers show great potential for the early detection of breast cancer.
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
50% of the breast cancers are localized at the time of diagnosis (2). Despite the availability and recommended use of mammography as a routine screening method for women 40 years of age and older, its effectiveness in reducing overall population mortality from breast cancer is still being investigated (3). Currently, serum tumor markers, such as CA15.3, that have been investigated for use in breast cancer detection still lack the adequate sensitivity (23%) and specificity (69%) to be applicable in detecting early-stage carcinoma in a large population (4). The Food and Drug Administration-approved tumor markers, such as CA15.3 and CA27.29, are recommended only for monitoring therapy of advanced breast cancer or recurrence (5). New biomarkers that could be used individually or in combination with an existing modality for cost-effective screening of breast cancer are still urgently needed. The classical approach for discovering disease-associated proteins is two-dimensional polyacrylamide gel electrophoresis (2D-PAGE).1 Although 2D-PAGE is unchallenged in its ability to resolve thousands of proteins, it is labor-intensive, requires large quantities of protein, and is not easily converted into a diagnostic test. Recent advances in mass spectrometry (MS), such as matrix-assisted laser desorption/ionization time-of-flight MS, are beginning to offer an alternative to 2D-PAGE. In this technique, purified or partially purified proteins are mixed with a crystal-forming matrix, placed on an inert metal target, and subjected to a pulsed laser beam to produce gas-phase ions that traverse a field-free flight tube and then are separated according to their mass-dependent velocities (m/z) (6). However, some limitations in matrix-assisted laser desorption/ionization, such as extensive sample preparation and signal background problems resulting from inorganic and organic contaminants, have hindered it from being used as a high-throughput screening tool for proteins of interest in complex biological samples. The development of surface-enhanced laser desorption/ionization time-of-flight (SELDI-TOF) MS (7), has largely overcome many of these limitations. SELDI is an affinity-based MS method in which proteins are selectively adsorbed to a chemically modified surface (Ciphergen ProteinChip® Arrays), and impurities are removed by washing with buffer. The use of several different chromatographic arrays and wash conditions enables high-speed, high-resolution chromatographic separations (8). This technology has been used successfully to detect several disease-associated proteins in complex biological specimens, such as cell lysates, seminal plasma, and serum (9)(10)(11)(12)(13).
SELDI-TOF MS offers high-throughput protein profiling. Like many other types of high-throughput expression data, protein array data are often characterized by a large number of variables (the mass peaks) relative to a small sample size (the number of specimens). An important issue in analyzing such data to screen for disease-associated biomarkers is to extract as much information as possible from a limited number of samples and to avoid selecting biomarkers whose performances are influenced mostly by non-disease-related artifacts in the data. The effective and appropriate use of bioinformatics tools becomes very critical.
Here we report the use of SELDI with immobilized metal affinity ProteinChip Arrays to screen for potential serum biomarkers for early detection of breast cancer. A total of 169 retrospective serum samples from patients with or without breast cancer were obtained from Johns Hopkins Clinical Chemistry serum banks and analyzed simultaneously. Proteins bound to the chelated metal (through histidine, tryptophan, cysteine, or phosphorylated amino acids) were analyzed on a ProteinChip Reader Model PBS II (Ciphergen Biosystems). The complex protein profiles were analyzed using a collection of bioinformatics tools. A panel of three biomarkers was selected based on their consistently significant contribution to the optimal separation of stage 0–I breast cancer patients vs the noncancer controls (healthy + benign). The effectiveness of the selected biomarkers was then tested using independent data from stage II–III breast cancer patients and through bootstrap cross-validation. Finally, correlation of the concentrations of these biomarkers to tumor size and lymph node metastasis was also investigated.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
proteinchip array analysis
To 20 µL of each serum sample, we added 30 µL of a solution containing 8 mol/L urea and 10 g/L CHAPS in phosphate-buffered saline, pH 7.4. The mixture was vortex-mixed at 4 °C for 15 min and diluted 1:40 (5 µL of mixture plus 195 µL of phosphate-buffered saline) in phosphate-buffered saline. Immobilized metal affinity capture arrays (IMAC3) were activated with 50 mmol/L NiSO4 according to manufacturer’s instructions (Ciphergen). Diluted samples (50 µL) were applied to each spot on the ProteinChip Array by a 96-well bioprocessor (Ciphergen). After the samples were allowed to bind at room temperature for 60 min on a platform shaker, the array was washed twice with 100 µL of phosphate-buffered saline for 5 min, followed by two quick rinses with 100 µL of distilled H2O. After air-drying, 0.5 µL of saturated sinapinic acid prepared in 500 mL/L acetonitrile–5 mL/L trifluoroacetic acid was applied twice to each spot. Proteins bound to the chelated metal (through histidine, tryptophan, cysteine, or phosphorylated amino acids) were detected with the ProteinChip Reader. Data were collected by averaging 80 laser shots with an intensity of 240 and a detector sensitivity of 8. Reproducibility was estimated using two representative serum samples: one from the healthy controls and one from the cancer patients. Each serum sample was spotted on all eight bait surfaces of one IMAC-Ni array in each of the two bioprocessors. The CV was estimated for the selected mass peaks.
bioinformatics and biostatistics
All spectra were compiled, and qualified mass peaks (signal-to-noise ratio >5) with mass-to-charge ratios (m/z) between 2000 and 150 000 were autodetected. Peak clusters were completed using second-pass peak selection (signal-to-noise ratio >2, within 0.3% mass window), and estimated peaks were added. The peak intensities were normalized to the total ion current of m/z between 2000 and 150 000. All these were performed using ProteinChip Software 3.0 (Ciphergen). The only additional preprocessing step was logarithmic transformation of the peak intensity data. Such a transformation in general reduces the range of intensity data. As a result, the variance of the transformed peak intensity (across multiple samples) tends to be less volatile over the entire length of the spectrum.
The software package ProPeak (3Z Informatics) was used to compute and rank the contribution of each individual peak toward the optimal separation of two diagnostic groups. ProPeak implements the linear version of the Unified Maximum Separability Analysis (UMSA) algorithm that was first reported for use in microarray data analysis (14). The key feature of the UMSA algorithm is the incorporation of data distribution information into a structural risk minimization learning algorithm (15) to identify a direction along which the two classes of data are best separated. This direction is represented as a linear combination (weighted sum) of the original variables. The weight assigned to each variable in this combination measures the contribution of the variable toward the separation of the two classes of data.
Currently, ProPeak offers three UMSA-based analytical modules. The first is the Component Analysis Module, which projects each specimen as an individual point onto a three-dimensional component space. The components (axes) are linear combinations of the original spectrum peak intensities. The axes correspond to the directions along which two prespecified groups of data achieve maximum separability. The separation between the two groups of data in the component space can be inspected in an interactive three-dimensional display. If the separation achieved using combinations of all peaks is acceptable for a particular problem, the second module of ProPeak, BootStrap Selection, is used to reduce the complexity of the original data set. This module performs multiple runs of UMSA. In each run, a fixed percentage of the samples is randomly left out from both groups. The mean, the median, and the corresponding SD of the ranks from multiple runs are estimated for each peak. The bootstrap- estimated SD of a peak’s rank provides the information about the consistency of the peak’s ranking across multiple randomly selected subpopulations of the samples. To establish an objective peak selection criterion, in this study the same bootstrap procedure was also applied to a random dataset that, peak by peak, simulates the distribution of the actual data. The minimum of the rank SDs among all peaks in the simulated random data set was used as the cutoff value for rank SD of the actual data to select a subset of peaks that, in addition to being top-ranked in their contribution to the separation of the data groups, also demonstrated a consistency that was less likely attributable to pure chance. Finally, the third module of ProPeak applies a backward stepwise selection procedure to compute a significance score for each peak. The absolute value of the score is based on the peak’s contribution to data separation and is in reverse relation to the order in which it is removed from the initial list of peaks. A positive or negative score indicates relatively increased or decreased expression, respectively, of the corresponding mass peak for the diseased group, whereas the absolute value of the score represents its relative importance toward data separation.
To identify potential biomarkers that can detect breast cancer at early stages, protein profiles of specimens from stage 0–I breast cancer patients were compared against those of the noncancer controls. The analysis involved multiple iterations using all three modules in ProPeak to select from the original full set of mass peaks a small panel of peaks that possessed a consistently high degree of significance in the optimal separation between the two selected diagnostic groups.
Once the small panel of biomarkers was selected, their ability to detect breast cancer was evaluated using the set-aside independent test data set of stages II and III cancer patients. To assess the complementary performance of multiple biomarkers, a composite index was derived using multivariate logistic regression based on the entire data set. Descriptive statistics including P values from two-sample t-tests and ROC curve analysis were provided for the selected individual biomarkers as well as the composite index. To partially overcome the limitation of lacking a full set of independent test data other than those from the late-stage cancer patients, we used the bootstrap procedure (16) to estimate key performance criteria such as the sensitivity and specificity of the composite index. In this procedure, the patient data set was repeatedly divided through random sampling into a training set to derive a composite index through logistic regression and a test set for computing sensitivities and specificities. The results from multiple runs were then aggregated to form the bootstrap estimate of sensitivity and specificity.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Among a total of 147 qualified mass peaks (signal-to-noise ratio >5) detected, 61 peaks had m/z values between 2 and 10 kDa, 30 peaks had m/z values between 10 and 20 kDa, 33 peaks were between 20 and 50 kDa, and 23 peaks were between 50 and 133 kDa. Peaks with a m/z <2 kDa were mainly ion noise from the matrix and therefore excluded. Peak intensity was normalized to total ion current (2–150 kDa), and logarithmic transformation was applied. The plots in Fig. 1
illustrate the effect of variance reduction and equalization through logarithmic transformation.
|
biomarker selection based on early-stage cancer and noncancer controls
To identify biomarkers with potential for early detection of breast cancer, UMSA was performed using early-stage cancer as the positive group (stage 0–I; n = 42) and the noncancer controls (HC + BN; n = 66) as the negative group. Separability between the two groups was first tested using UMSA-derived liner combination of all 147 mass peaks. The early-stage cancer was separable from the noncancer group when the entire protein profiles were compared. Fig. 2A
provides a snapshot of the early-stage cancer (red) and the noncancer (green) data in the UMSA component three-dimensional space.
|
To select biomarkers with consistent performance, we repeatedly applied UMSA for a total of 100 runs, each with a 30% leave-out rate, using the ProPeak BootStrap module. We also applied the same procedure to a simulated random data set. The minimal rank SD derived from the simulated data was 7.0. Among the peaks with top mean ranks from the actual experimental data, 15 had a rank SD less than this value. They were selected as candidate biomarkers for further analysis. Their mean ranks and the corresponding rank SDs are plotted in Fig. 3
.
|
To further rank the peaks in this reduced set of candidate biomarkers, we used the Stepwise Selection module of ProPeak. The absolute value of the relative significance scores of the 15 peaks are plotted in descending order in Fig. 4A
, which shows that the majority of separability between the two groups of data was contributed by the first six peaks. Among these six peaks, two were identified by ProteinChip Software 3.0 as doubly charged forms of the others. The recognition of both the doubly charged and the singly charged forms of these peaks suggests their importance in discriminating the selected two diagnostic groups. Excluding the doubly charged forms, the four unique peaks were further recombined and evaluated using the Backward Stepwise Selection module of ProPeak. The recalculated relative significance scores are plotted in Fig. 4B
. The top-scored three peaks, designated BC1 (4.3 kDa), BC2 (8.1 kDa), and BC3 (8.9 kDa), were finally selected as the potential biomarkers for detection of breast cancer. Snapshots of three-dimensional plots of stage 0–I or stage 0–III breast cancer against the noncancer controls using these three biomarkers are shown in Fig. 2
, panels B and C, respectively. Among the three biomarkers, BC1 appeared to be down-regulated (scored negative; data not shown), whereas BC2 and BC3 were up-regulated (scored positive; data not shown). This is easily seen in Fig. 5
, in which representative spectra and gel views of the selected biomarkers are compared between cancer and noncancer controls.
|
|
evaluation of the selected biomarkers
The estimated CVs of the log-transformed peak intensities were 6% for BC1, 7% for BC2, and 13% for BC3 (data not shown). Among the three biomarkers, BC3 had the largest CV of 13%. The descriptive statistics of these three biomarkers are listed in Table 1
. Fig. 6
shows results from the ROC analysis. Among the three biomarkers, BC3 possesses the highest individual diagnostic power [area under the curve (AUC), 0.934] compared with BC1 (AUC, 0.846) and BC2 (AUC, 0.795). Its distributions over the diagnostic groups including clinical stages of cancer patients are plotted in Fig. 7A
. The sensitivities and specificities of using BC3 alone at a cutoff value of 0.8 to differentiate the diagnostic groups are listed in Table 2
A. The overall sensitivity for breast cancer was 85%, and specificity was 91%.
|
|
|
|
combined use of three selected biomarkers
Multivariate logistic regression was used to combine the three selected biomarkers to form a single-value composite index. The descriptive statistics of this composite index are appended in Table 1
. Its distributions over the various diagnostic groups are plotted in Fig. 7B
. ROC curve analysis of the composite index gave a much improved AUC (0.972) compared with the AUCs from individual biomarkers (Fig. 6
).
Bootstrap cross-validation was used to estimate the diagnostic performance of the composite index (20 runs; in each run, 70% samples were randomly selected for composite index derivation and the remaining 30% for testing). The estimated sensitivity (93%) and specificity (91%) are listed in Table 2
B.
correlation to tumor size and lymph node metastasis
The concentrations of the three potential biomarkers were evaluated in relation to pT (tumor size) and pN (lymph node metastasis) categories. No significant correlation was observed (data not shown).
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Taking advantage of the recent development in SELDI and of the ProteinChip technology, we were able to simultaneously analyze the protein profiles of 169 serum samples from patients with or without breast cancer. The software package ProPeak allows evaluation of each mass peak according to its collective contribution toward the maximal separation of the cancer patients from the noncancer controls. These two advances led to the identification of three discriminatory biomarkers that, in combination, achieved both high sensitivity (93%) and high specificity (91%) in detecting breast cancer patients from the noncancer controls.
Early detection remains one of the most urgent issues in breast cancer research. To find biomarkers particularly sensitive to differences between early-stage breast cancer patients and noncancer controls, the selection of mass peaks reported here was performed using stage 0–I cancer and noncancer controls as the training data and later-stage cancer as test data. However, the biomarkers that were used in the final selection were not sensitive to the stages of cancer patients used in the selection process. In fact, whether the combinations used were stage II vs noncancer, stage III vs noncancer, or a randomly selected subset of cancer patients at all stages against noncancer controls, the same three peaks were always selected as the best and most consistently ranked biomarkers.
High-throughput profiling of complex protein expression patterns greatly facilitates the screening of a large number of potential markers simultaneously. However, for most currently available data sets, the sample sizes are relatively small compared with the total number of detected mass peaks. There is a real danger to mistakenly select mass peaks whose high discriminatory power is purely by chance because of artifacts in the data that are unrelated to the disease process. The use of high-order nonlinear classification models directly on raw spectrum data may further amplify and mask the influence of such false markers.
In this study, the UMSA algorithm provided an efficient model to rank a large number of peaks collectively according to their contribution to the separation of two predefined diagnostic groups. The ProPeak BootStrap module introduced random perturbations in multiple runs to test the consistency of the top-ranked peaks, measured by the SD of computed ranks from multiple runs. To establish an upper cutoff value on a peak’s rank SD for its performance not to be considered as purely by chance, the same bootstrap procedure was applied to a randomly generated data set that simulated the distribution of the real data. The minimum value of rank SDs from such "simulated peaks" indicates the degree of consistency that a peak might achieve by random chance. This minimum value was used as the cutoff to help to reduce the original 147 peaks to a subset of 15 peaks for further consideration. The performance of such peaks should be less likely attributable to random artifacts in the data.
For simplicity, the composite index described in this report was derived by simple multivariate logistic regression. When these selected biomarkers are further validated, more complex and nonlinear classification models may be used to combine the multiple biomarkers. The use of complex modeling methods on carefully screened and tested biomarkers should in general offer a more robust performance than the direct application of such methods on raw data from a large number of mass peaks.
The number of specimens analyzed in this study to some degree limited the validity of the results. The bootstrap cross-validation estimation of performance offers statistical confidence on the generalizability of these biomarkers over future data. Further independent validation studies are needed. In such studies, the specificity of these selected biomarkers for detection of breast cancer needs to be addressed by testing specimens from other types of cancer. In addition, validation data sets preferably should be from sources different from that of the original training data set. This is one way to ensure that the performance of the selected biomarkers is not influenced by systematic biases between the disease and the control specimens.
For the three biomarkers selected, no significant correlation was found between the concentrations of the markers and tumor size or lymph node metastasis. The discriminatory power of these markers therefore most likely reflects the malignant nature of the tumor rather than its progression. The origin and identity of BC1, BC2, and BC3 are currently under investigation. Furthermore, it is not our intent at this stage to suggest a final diagnostic algorithm based on nonlinear classification.
In conclusion, we have shown that using proteomics approaches such as Ciphergen ProteinChip Arrays and SELDI-TOF MS in combination with bioinformatics tools could facilitate the discovery of new biomarkers. Using the panel of three selected biomarkers, we could achieve high sensitivity and specificity for the detection of breast cancer.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  P. de Valpine, H.-M. Bitter, M. P. S. Brown, and J. Heller A simulation-approximation approach to sample size planning for high-dimensional classification studies Biostat., July 1, 2009; 10(3): 424 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. ZEIDAN, R. I. CUTRESS, N. MURRAY, G. R. COULTON, C. HASTIE, G. PACKHAM, and P. A. TOWNSEND Proteomic Analysis of Archival Breast Cancer Serum Cancer Genomics Proteomics, May 1, 2009; 6(3): 141 - 147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, R. L. SCHWIRZ, and F. H. GRUS Diagnosis of Breast Cancer by Tear Proteomic Pattern Cancer Genomics Proteomics, May 1, 2009; 6(3): 177 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ocak, P. Chaurand, and P. P. Massion Mass Spectrometry-based Proteomic Profiling of Lung Cancer Proceedings of the ATS, April 15, 2009; 6(2): 159 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Matsumoto, T. Kojima, K. Ogawa, S. Kamegai, T. Oyama, Y. Shibagaki, T. Kawasaki, H. Fujinaga, K. Takahashi, H. Hikiami, et al. A Proteomic Approach for the Diagnosis of 'Oketsu' (blood stasis), a Pathophysiologic Concept of Japanese Traditional (Kampo) Medicine Evid. Based Complement. Altern. Med., December 1, 2008; 5(4): 463 - 474. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. McLerran, W. E. Grizzle, Z. Feng, W. L. Bigbee, L. L. Banez, L. H. Cazares, D. W. Chan, J. Diaz, E. Izbicka, J. Kagan, et al. Analytical Validation of Serum Proteomic Profiling for Diagnosis of Prostate Cancer: Sources of Sample Bias Clin. Chem., January 1, 2008; 54(1): 44 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Zhang and D. W. Chan Cancer Biomarker Discovery in Plasma Using a Tissue-targeted Proteomic Approach Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1915 - 1917. [Full Text] [PDF]
|
|
|
|
|
|
H. Dihazi, G. A. Muller, S. Lindner, M. Meyer, A. R. Asif, M. Oellerich, and F. Strutz Characterization of Diabetic Nephropathy by Urinary Proteomic Analysis: Identification of a Processed Ubiquitin Form as a Differentially Excreted Protein in Diabetic Nephropathy Patients Clin. Chem., September 1, 2007; 53(9): 1636 - 1645. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. McIlwain, D. Page, E. L. Huttlin, and M. R. Sussman Using dynamic programming to create isotopic distribution maps from mass spectra Bioinformatics, July 1, 2007; 23(13): i328 - i336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Lopez, A. Mikulskis, S. Kuzdzal, E. Golenko, E. F. Petricoin III, L. A. Liotta, W. F. Patton, G. R. Whiteley, K. Rosenblatt, P. Gurnani, et al. A Novel, High-Throughput Workflow for Discovery and Identification of Serum Carrier Protein-Bound Peptide Biomarker Candidates in Ovarian Cancer Samples Clin. Chem., June 1, 2007; 53(6): 1067 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. H. Otu, H. Can, D. Spentzos, R. G. Nelson, R. L. Hanson, H. C. Looker, W. C. Knowler, M. Monroy, T. A. Libermann, S. A. Karumanchi, et al. Prediction of Diabetic Nephropathy Using Urine Proteomic Profiling 10 Years Prior to Development of Nephropathy Diabetes Care, March 1, 2007; 30(3): 638 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Aivado, D. Spentzos, U. Germing, G. Alterovitz, X.-Y. Meng, F. Grall, A. A. N. Giagounidis, G. Klement, U. Steidl, H. H. Otu, et al. From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease PNAS, January 23, 2007; 104(4): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Qiu, Z. J. Wang, K. J. R. Liu, Z.-Z. Hu, and C. H. Wu Dependence network modeling for biomarker identification Bioinformatics, January 15, 2007; 23(2): 198 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Guo, Z. Fu, and J. E. Van Eyk A Proteomic Primer for the Clinician Proceedings of the ATS, January 1, 2007; 4(1): 9 - 17. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Nakagawa, S. K. Huang, S. R. Martinez, A. N. Tran, D. Elashoff, X. Ye, R. R. Turner, A. E. Giuliano, and D. S.B. Hoon Proteomic Profiling of Primary Breast Cancer Predicts Axillary Lymph Node Metastasis Cancer Res., December 15, 2006; 66(24): 11825 - 11830. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Drake, E. E. Schwegler, G. Malik, J. Diaz, T. Block, A. Mehta, and O. J. Semmes Lectin Capture Strategies Combined with Mass Spectrometry for the Discovery of Serum Glycoprotein Biomarkers Mol. Cell. Proteomics, October 1, 2006; 5(10): 1957 - 1967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Villanueva, A. J. Martorella, K. Lawlor, J. Philip, M. Fleisher, R. J. Robbins, and P. Tempst Serum Peptidome Patterns That Distinguish Metastatic Thyroid Carcinoma from Cancer-free Controls Are Unbiased by Gender and Age Mol. Cell. Proteomics, October 1, 2006; 5(10): 1840 - 1852. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Yang, L. E. Harris, D. E. Palmer-Toy, and W. S. Hancock Multilectin Affinity Chromatography for Characterization of Multiple Glycoprotein Biomarker Candidates in Serum from Breast Cancer Patients Clin. Chem., October 1, 2006; 52(10): 1897 - 1905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. C. Ru, L. A. Zhu, J. Silberman, and C. D. Shriver Label-free Semiquantitative Peptide Feature Profiling of Human Breast Cancer and Breast Disease Sera via Two-dimensional Liquid Chromatography-Mass Spectrometry Mol. Cell. Proteomics, June 1, 2006; 5(6): 1095 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, Z. Zhang, and D. W. Chan Validation of Breast Cancer Biomarkers Identified by Mass Spectrometry: Some of the authors of the article cited above respond: Clin. Chem., April 1, 2006; 52(4): 772 - 772. [Full Text] [PDF]
|
|
|
|
|
|
R. S. Dua, C. M. Isacke, and G. P.H. Gui The Intraductal Approach to Breast Cancer Biomarker Discovery J. Clin. Oncol., March 1, 2006; 24(7): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Li, J. Zhao, X. Yu, J. Lange, H. Kuerer, S. Krishnamurthy, E. Schilling, S. A. Khan, S. Sukumar, and D. W. Chan Identification of Biomarkers for Breast Cancer in Nipple Aspiration and Ductal Lavage Fluid Clin. Cancer Res., December 1, 2005; 11(23): 8312 - 8320. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Li, R. Orlandi, C. N. White, J. Rosenzweig, J. Zhao, E. Seregni, D. Morelli, Y. Yu, X.-Y. Meng, Z. Zhang, et al. Independent Validation of Candidate Breast Cancer Serum Biomarkers Identified by Mass Spectrometry Clin. Chem., December 1, 2005; 51(12): 2229 - 2235. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-J. Cheng, L.-C. Chen, K.-Y. Chien, Y.-J. Chen, J. T.-C. Chang, H.-M. Wang, C.-T. Liao, and I-H. Chen Oral Cancer Plasma Tumor Marker Identified with Bead-Based Affinity-Fractionated Proteomic Technology Clin. Chem., December 1, 2005; 51(12): 2236 - 2244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. Ressom, R. S. Varghese, M. Abdel-Hamid, S. A.-L. Eissa, D. Saha, L. Goldman, E. F. Petricoin, T. P. Conrads, T. D. Veenstra, C. A. Loffredo, et al. Analysis of mass spectral serum profiles for biomarker selection Bioinformatics, November 1, 2005; 21(21): 4039 - 4045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Banks, A. J. Stanley, D. A. Cairns, J. H. Barrett, P. Clarke, D. Thompson, and P. J. Selby Influences of Blood Sample Processing on Low-Molecular-Weight Proteome Identified by Surface-Enhanced Laser Desorption/Ionization Mass Spectrometry Clin. Chem., September 1, 2005; 51(9): 1637 - 1649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. Robbins, J. Villanueva, and P. Tempst Distilling Cancer Biomarkers From the Serum Peptidome: High Technology Reading of Tea Leaves or an Insight to Clinical Systems Biology? J. Clin. Oncol., August 1, 2005; 23(22): 4835 - 4837. [Full Text] [PDF]
|
|
|
|
|
|
S. Mian, S. Ugurel, E. Parkinson, I. Schlenzka, I. Dryden, L. Lancashire, G. Ball, C. Creaser, R. Rees, and D. Schadendorf Serum Proteomic Fingerprinting Discriminates Between Clinical Stages and Predicts Disease Progression in Melanoma Patients J. Clin. Oncol., August 1, 2005; 23(22): 5088 - 5093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Karsan, B. J. Eigl, S. Flibotte, K. Gelmon, P. Switzer, P. Hassell, D. Harrison, J. Law, M. Hayes, M. Stillwell, et al. Analytical and Preanalytical Biases in Serum Proteomic Pattern Analysis for Breast Cancer Diagnosis Clin. Chem., August 1, 2005; 51(8): 1525 - 1528. [Full Text] [PDF]
|
|
|
|
|
|
N. Jeffries Algorithms for alignment of mass spectrometry proteomic data Bioinformatics, July 15, 2005; 21(14): 3066 - 3073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kim, P. Sun, Y.-W. Lam, P. Troncoso, A. L. Sabichi, R. J. Babaian, L. L. Pisters, C. A. Pettaway, C. G. Wood, S. M. Lippman, et al. Changes in Serum Proteomic Patterns by Presurgical {alpha}-Tocopherol and L-Selenomethionine Supplementation in Prostate Cancer Cancer Epidemiol. Biomarkers Prev., July 1, 2005; 14(7): 1697 - 1702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F M Brouwers, E F Petricoin III, L Ksinantova, J Breza, V Rajapakse, S Ross, D Johann, M Mannelli, B L Shulkin, R Kvetnansky, et al. Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma Endocr. Relat. Cancer, June 1, 2005; 12(2): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Streckfus and L. Bigler The Use of Soluble, Salivary c-erbB-2 for the Detection and Post-operative Follow-up of Breast Cancer in Women: The Results of a Five-year Translational Research Study Advances in Dental Research, June 1, 2005; 18(1): 17 - 24. [Full Text] [PDF]
|
|
|
|
|
|
H. Bensmail, J. Golek, M. M. Moody, J. O. Semmes, and A. Haoudi A novel approach for clustering proteomics data using Bayesian fast Fourier transform Bioinformatics, May 15, 2005; 21(10): 2210 - 2224. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Meyerson and D. Carbone Genomic and Proteomic Profiling of Lung Cancers: Lung Cancer Classification in the Age of Targeted Therapy J. Clin. Oncol., May 10, 2005; 23(14): 3219 - 3226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Le, K. Chi, S. Tyldesley, S. Flibotte, D. L. Diamond, M. A. Kuzyk, and M. D. Sadar Identification of Serum Amyloid A as a Biomarker to Distinguish Prostate Cancer Patients with Bone Lesions Clin. Chem., April 1, 2005; 51(4): 695 - 707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Grus, V. N. Podust, K. Bruns, K. Lackner, S. Fu, E. A. Dalmasso, A. Wirthlin, and N. Pfeiffer SELDI-TOF-MS ProteinChip Array Profiling of Tears from Patients with Dry Eye Invest. Ophthalmol. Vis. Sci., March 1, 2005; 46(3): 863 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Liotta, M. Lowenthal, A. Mehta, T. P. Conrads, T. D. Veenstra, D. A. Fishman, and E. F. Petricoin III Importance of Communication Between Producers and Consumers of Publicly Available Experimental Data J Natl Cancer Inst, February 16, 2005; 97(4): 310 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Malik, M. D. Ward, S. K. Gupta, M. W. Trosset, W. E. Grizzle, B.-L. Adam, J. I. Diaz, and O. J. Semmes Serum Levels of an Isoform of Apolipoprotein A-II as a Potential Marker for Prostate Cancer Clin. Cancer Res., February 1, 2005; 11(3): 1073 - 1085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Koomen, L. N. Shih, K. R. Coombes, D. Li, L.-c. Xiao, I. J. Fidler, J. L. Abbruzzese, and R. Kobayashi Plasma Protein Profiling for Diagnosis of Pancreatic Cancer Reveals the Presence of Host Response Proteins Clin. Cancer Res., February 1, 2005; 11(3): 1110 - 1118. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Posadas, F. Simpkins, L. A. Liotta, C. MacDonald, and E. C. Kohn Proteomic analysis for the early detection and rational treatment of cancer--realistic hope? Ann. Onc., January 1, 2005; 16(1): 16 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. J. Semmes, Z. Feng, B.-L. Adam, L. L. Banez, W. L. Bigbee, D. Campos, L. H. Cazares, D. W. Chan, W. E. Grizzle, E. Izbicka, et al. Evaluation of Serum Protein Profiling by Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry for the Detection of Prostate Cancer: I. Assessment of Platform Reproducibility Clin. Chem., January 1, 2005; 51(1): 102 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-d. Chen, S. Zheng, J.-k. Yu, and X. Hu Artificial Neural Networks Analysis of Surface-Enhanced Laser Desorption/Ionization Mass Spectra of Serum Protein Pattern Distinguishes Colorectal Cancer from Healthy Population Clin. Cancer Res., December 15, 2004; 10(24): 8380 - 8385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rej Clinical Chemistry through Clinical Chemistry: A Journal Timeline Clin. Chem., December 1, 2004; 50(12): 2415 - 2458. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. O'Riordan, T. N. Orlova, J. Mei J, K. Butt, P. M. Chander, S. Rahman, M. Mya, R. Hu, J. Momin, E. W. Eng, et al. Bioinformatic Analysis of the Urine Proteome of Acute Allograft Rejection J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3240 - 3248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, R. C. Bast Jr., Y. Yu, J. Li, L. J. Sokoll, A. J. Rai, J. M. Rosenzweig, B. Cameron, Y. Y. Wang, X.-Y. Meng, et al. Three Biomarkers Identified from Serum Proteomic Analysis for the Detection of Early Stage Ovarian Cancer Cancer Res., August 15, 2004; 64(16): 5882 - 5890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vlahou, A. Giannopoulos, B. W. Gregory, T. Manousakas, F. I. Kondylis, L. L. Wilson, P. F. Schellhammer, G. L. Wright Jr, and O. J. Semmes Protein Profiling in Urine for the Diagnosis of Bladder Cancer Clin. Chem., August 1, 2004; 50(8): 1438 - 1441. [Full Text] [PDF]
|
|
|
|
|
|
S. G. Soltys, Q.-T. Le, G. Shi, R. Tibshirani, A. J. Giaccia, and A. C. Koong The Use of Plasma Surface-Enhanced Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Proteomic Patterns for Detection of Head and Neck Squamous Cell Cancers Clin. Cancer Res., July 15, 2004; 10(14): 4806 - 4812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Xiao, B. T. Luke, G. Izmirlian, A. Umar, P. M. Lynch, R. K. S. Phillips, S. Patterson, T. P. Conrads, T. D. Veenstra, P. Greenwald, et al. Serum Proteomic Profiles Suggest Celecoxib-Modulated Targets and Response Predictors Cancer Res., April 15, 2004; 64(8): 2904 - 2909. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Jacobs and U. Menon Progress and Challenges in Screening for Early Detection of Ovarian Cancer Mol. Cell. Proteomics, April 1, 2004; 3(4): 355 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Analysis of Serum Proteomic Patterns for Early Cancer Diagnosis: Drawing Attention to Potential Problems J Natl Cancer Inst, March 3, 2004; 96(5): 353 - 356. [Full Text] [PDF]
|
|
|
|
|
|
J. T. Wadsworth, K. D. Somers, L. H. Cazares, G. Malik, B.-L. Adam, B. C. Stack Jr., G. L. Wright Jr., and O. J. Semmes Serum Protein Profiles to Identify Head and Neck Cancer Clin. Cancer Res., March 1, 2004; 10(5): 1625 - 1632. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lumbreras-Lacarra, J. M. Ramos-Rincon, and I. Hernandez-Aguado Methodology in Diagnostic Laboratory Test Research in Clinical Chemistry and Clinical Chemistry and Laboratory Medicine Clin. Chem., March 1, 2004; 50(3): 530 - 536. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Geho, E. F. Petricoin, and L. A. Liotta Blasting into the Microworld of Tissue Proteomics: A New Window on Cancer: Commentary re S. A. Schwartz et al., Protein Profiling in Brain Tumors Using Mass Spectrometry: Feasibility of a New Technique for the Analysis of Protein Expression. Clin. Cancer Res., 10: 981-987, 2004. Clin. Cancer Res., February 1, 2004; 10(3): 825 - 827. [Full Text] [PDF]
|
|
|
|
|
|
J. Koopmann, Z. Zhang, N. White, J. Rosenzweig, N. Fedarko, S. Jagannath, M. I. Canto, C. J. Yeo, D. W. Chan, and M. Goggins Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry Clin. Cancer Res., February 1, 2004; 10(3): 860 - 868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. T. Wadsworth, K. D. Somers, B. C. Stack Jr, L. Cazares, G. Malik, B.-L. Adam, G. L. Wright Jr, and O. J. Semmes Identification of Patients With Head and Neck Cancer Using Serum Protein Profiles Arch Otolaryngol Head Neck Surg, January 1, 2004; 130(1): 98 - 104. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. F. Petricoin, V. Rajapaske, E. H. Herman, A. M. Arekani, S. Ross, D. Johann, A. Knapton, J. Zhang, B. A. Hitt, T. P. Conrads, et al. Toxicoproteomics: Serum Proteomic Pattern Diagnostics for Early Detection of Drug Induced Cardiac Toxicities and Cardioprotection Toxicol Pathol, January 1, 2004; 32(1_suppl): 122 - 130. [Abstract] [PDF]
|
|
|
|
|
|
W. Zhu, X. Wang, Y. Ma, M. Rao, J. Glimm, and J. S. Kovach Detection of cancer-specific markers amid massive mass spectral data PNAS, December 9, 2003; 100(25): 14666 - 14671. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Sidransky, R. Irizarry, J. A. Califano, X. Li, H. Ren, N. Benoit, and L. Mao Serum Protein MALDI Profiling to Distinguish Upper Aerodigestive Tract Cancer Patients From Control Subjects J Natl Cancer Inst, November 19, 2003; 95(22): 1711 - 1717. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Rogers, P. Clarke, J. Noble, N. P. Munro, A. Paul, P. J. Selby, and R. E. Banks Proteomic Profiling of Urinary Proteins in Renal Cancer by Surface Enhanced Laser Desorption Ionization and Neural-Network Analysis: Identification of Key Issues Affecting Potential Clinical Utility Cancer Res., October 15, 2003; 63(20): 6971 - 6983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. R. Kozak, M. W. Amneus, S. M. Pusey, F. Su, M. N. Luong, S. A. Luong, S. T. Reddy, and R. Farias-Eisner Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: Potential use in diagnosis and prognosis PNAS, October 14, 2003; 100(21): 12343 - 12348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. P. Diamandis Proteomic Patterns in Biological Fluids: Do They Represent the Future of Cancer Diagnostics? Clin. Chem., August 1, 2003; 49(8): 1272 - 1275. [Full Text] [PDF]
|
|
|
|
|
|
E. Petricoin III and L. A. Liotta The Vision for a New Diagnostic Paradigm Clin. Chem., August 1, 2003; 49(8): 1276 - 1278. [Full Text] [PDF]
|
|
|
|
|
|
T. C.W. Poon, T.-T. Yip, A. T.C. Chan, C. Yip, V. Yip, T. S.K. Mok, C. C.Y. Lee, T. W.T. Leung, S. K.W. Ho, and P. J. Johnson Comprehensive Proteomic Profiling Identifies Serum Proteomic Signatures for Detection of Hepatocellular Carcinoma and Its Subtypes Clin. Chem., May 1, 2003; 49(5): 752 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hondermarck Breast Cancer: When Proteomics Challenges Biological Complexity Mol. Cell. Proteomics, May 1, 2003; 2(5): 281 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin and L. A. Liotta Mass Spectrometry-based Diagnostics: The Upcoming Revolution in Disease Detection Clin. Chem., April 1, 2003; 49(4): 533 - 534. [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Colburn Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing J. Clin. Pharmacol., April 1, 2003; 43(4): 329 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Petricoin III and L. A. Liotta RESPONSE: Re: Serum Proteomic Patterns for Detection of Prostate Cancer J Natl Cancer Inst, March 19, 2003; 95(6): 490 - 491. [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) and minimal rank SDs (
) derived from ProPeak Bootstrap Analysis.
), BC3 (
), and logistic regression-derived composite index (+).